Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03196167 · ClinicalTrials.gov registry record · Phase 4
Sugammadex and Decreased Time to Extubation
A Phase 4 study of Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT03196167: Completed Phase 4 study of Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery, sponsored by Yale University.
NCT03196167 is a Phase 4 study of Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery that has completed, run by Yale University. The registered enrollment target is 90 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03196167, a Phase 4 study of Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate faster time to extubation after arrival in the cardiothoracic intensive care unit (ICU) in patients undergoing isolated coronary artery bypass grafting (CABG), AVR and AVR/CABG combination who receive Sugammadex as compared to placebo.
Primary Outcome
The primary outcome of this study aims to test the time to extubation among patients in the cardiothoracic ICU who have undergone isolated CABG.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sugammadex
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2017-05-13 |
| Est. Completion | 2020-10-10 |
| Phase | Phase 4 |
What the finished NCT03196167 record still lists
NCT03196167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03196167 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03196167 about?
NCT03196167 is a clinical study titled "Sugammadex and Decreased Time to Extubation". The purpose of this study is to demonstrate faster time to extubation after arrival in the cardiothoracic intensive care unit (ICU) in patients undergoing isolated coronary artery bypass grafting (CABG), AVR and AVR/CABG combination who receive Sugammadex as compared to placebo.
What is the current status of trial NCT03196167?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2017-05-13. Estimated completion is 2020-10-10.
What conditions does trial NCT03196167 study?
This clinical trial studies the following conditions: Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery.
What interventions are being tested in trial NCT03196167?
The interventions under investigation include: Placebo (OTHER), Sugammadex (DRUG).
Who is sponsoring clinical trial NCT03196167?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03196167 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03196167's enrollment target sits among peer trials
90 886th of 2000 higher than 1,088 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI